Evaxion A/S (EVAX) vs Jasper Therapeutics (JSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evaxion A/S (EVAX) has outperformed Jasper Therapeutics (JSPR) over the past year, losing 51.5% versus a loss of 76.7%. Over five years, EVAX leads with a -99.2% price change compared with -99.7% for JSPR. Evaxion A/S is the larger company by market cap ($27.5 million vs $18.6 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVAX | JSPR |
|---|---|---|
| Share price | $3.05 | $0.56 |
| Market cap | $27.52M | $18.63M |
| 1-day change | -2.87% | -1.70% |
| YTD return | -36.06% | -69.40% |
| 1-year return | -51.51% | -76.67% |
| 5-year return | -99.23% | -99.66% |
| EPS (TTM) | $-1.00 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.15 | $2.69 |
| 52-week low | $2.77 | $0.315 |
| Distance from 52-week high | -74.90% | -79.18% |
| Analyst consensus | none | none |
| Avg. price target upside | +268.85% | +3471.43% |
| Average volume | 200.14K | 1.37M |
| Shares outstanding | 9.02M | 33.27M |
| Employees | 46 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EVAX has outperformed JSPR by 25.2 percentage points over the past year.
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Healthcare · Biotechnology · 46 employees
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Healthcare · Biotechnology
EVAX vs JSPR FAQ
Which is bigger, Evaxion A/S or Jasper Therapeutics?
Evaxion A/S (EVAX) is larger, with a market capitalization of $27.52M compared with $18.63M for Jasper Therapeutics (JSPR).
Which stock has performed better over the past year, EVAX or JSPR?
EVAX returned -51.51% over the past 12 months, compared with -76.67% for JSPR (price return, excluding dividends). Past performance does not predict future results.
Are Evaxion A/S and Jasper Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.